Shikonin reverses pyruvate kinase isoform M2‐mediated propranolol resistance in infantile hemangioma through reactive oxygen species‐induced autophagic dysfunction
Cancer Science · 2023-03 · 114 (3) · 806-821
DOI: 10.1111/cas.15649 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, online erschienen am 29.11.2022. Verfasst von Enli Yang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral and Maxillofacial Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China. Hauptthemen laut MEDLINE: Hemangioma, Skin Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Shandong Province.
Abstract (Originalsprache)
Infantile hemangioma (IH) is the most common benign tumor in infancy. Propranolol, a nonselective β‐adrenergic receptor blocker, is now the first‐line therapy for IH. Recently, low sensitivity to propranolol therapy has become one major reason for the failure of IH treatment. However, the exact underlying mechanisms are yet to be fully elucidated. Here, we reported that pyruvate kinase isoform M2 (PKM2), an essential glycolytic enzyme, played a critical role in regulating the progression of IH and the therapeutic resistance of propranolol treatment. Shikonin reversed the propranolol resistance in hemangioma‐derived endothelial cells and in hemangioma animal models. Moreover, shikonin combined with propranolol could induce excessive reactive oxygen species (ROS) accumulation and lead to autophagic dysfunction, which is essential for the enhanced therapeutic sensitivity of propranolol treatment. Taken together, our results indicated that PKM2 has a significant role in hemangiomas progression and therapeutic resistance; it could be a safe and effective therapeutic strategy for those hemangiomas with poor propranolol sensitivity combined with shikonin.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oral and Maxillofacial Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
- Department of Oral and Maxillofacial Surgery, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
- Department of Hemangioma, Shandong Provincial Third Hospital, Jinan, China.
ORCID-Profile: Haiwei Wu
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Shandong Province
Zitieren
APA
Yang, E., Wang, X., Huang, S., Li, M., Li, Y., Geng, Y., Liu, X., Chen, Z., Zhang, D., & Wu, H. (2023). Shikonin reverses pyruvate kinase isoform M2‐mediated propranolol resistance in infantile hemangioma through reactive oxygen species‐induced autophagic dysfunction. Cancer Science, 114(3), 806-821. https://doi.org/10.1111/cas.15649
Vancouver
Yang E, Wang X, Huang S, Li M, Li Y, Geng Y, et al. Shikonin reverses pyruvate kinase isoform M2‐mediated propranolol resistance in infantile hemangioma through reactive oxygen species‐induced autophagic dysfunction. Cancer Science. 2023;114(3):806-821. doi:10.1111/cas.15649
BibTeX
@article{Yang2023,
author = {Yang, Enli and Wang, Xuan and Huang, Shengyun and Li, Mingyang and Li, Yiming and Geng, Yiming and Liu, Xuejian and Chen, Zhanwei and Zhang, Dongsheng and Wu, Haiwei},
title = {Shikonin reverses pyruvate kinase isoform M2‐mediated propranolol resistance in infantile hemangioma through reactive oxygen species‐induced autophagic dysfunction},
journal = {Cancer Science},
year = {2023},
volume = {114},
number = {3},
pages = {806--821},
doi = {10.1111/cas.15649}
}
EUVIMED